Professor
Email: mi.liu@suda.edu.cn
Add: Room 1435, Yunxuan Building, Suzhou
Biography
He received his M.S from the School of Pharmaceutical Sciences of Peking University in 2010, received his Ph.D from the Drug Formulation & Delivery lab in Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zürich (ETH Zürich) in Switzerland in 2014, and received postdoctoral training from Department of Immunobiology at Harvard Medical School. In December 2018, he joined the Institute of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University as a professor.
As the corresponding author or the first author, he has published papers in the high quality journals including Nature Communications, Advanced Materials, Advanced Functional Materials, Advanced Science, Analytical Chemistry and iScience eta., and some papers have been published as cover and highlight papers.
The research is practical and has close cooperation with pharmaceutical enterprises. Several projects have successfully transferred to pharmaceutical companies. As the first inventor, he has applied for more than 40 international invention patents and Chinese invention patents on preventive and therapeutic cancer vaccine, cancer cell specific detection technology, mRNA vaccine delivery technology and immune multi-target detection technology etc., among which 12 have been authorized. Some international invention patents have entered the United States, the European Union, Japan, Canada, South Korea, Australia and Brazil. 11 invention patents have been successfully transferred to biopharmaceutical enterprises.
Research Interests
(1) Preventive and therapeutic cancer vaccines
(2) Novel T cell therapy
(3) Novel delivery technology of mRNA vaccine
(4) Novel detection technology of cancer cells
(5) Novel Multi-target immune detection technology
(6) Analmsis of cancer immune microenvironment
Recent Publications
(1) Lu Diao,Mi Liu*, Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell, Advanced Science, 2023,https://doi.org/10.1002/advs.202300121（1区，IF=17.521)
(2)LuDiao#,XiaoyanLiu#,MingzeChai#,JianjunLi#,YuWang,WenyongGao,HaishengLiu*,MiLiu*,LinChen*，Clinical trial of intrathecal injection of protein polymers for apoplexy: A protocol，Journal of Neurorestoratology, 2023, 11(2), 100052
(3) Lu Diao,Lin Ma,Junping Cheng,Yunzhi Pan,Zuofu Peng,Lianjun Zhang,Minghao Xu,Yupei Li,Xuenong Zhang,Honglv Jiang,Guoqiang Xu,Fenghua Meng,Zhiyuan Zhong,andMi Liu*, Across-cancer specific immune responses induced by nanovaccines or microvaccines to prevent different cancers and cancer metastasis, iScience, 2022, 25,105511 (1区，IF=6.107).
(4) Afang Ji#, Minghao Xu#, Yunzhi Pan#, Lu Diao, Lin Ma, Li Qian, Junping Cheng*,Mi Liu*，Lipid microparticles show similar efficacy with lipid nanoparticles in delivering mRNA and preventing cancer，Pharmaceutical Research, 2023,40(1),265-279 (2区，IF=4.580).
(5) Jianting Ma, Zuofu Peng, Lin Ma, Lu Diao, Xinyu Shao, Zhiming Zhao, Lele Liu, Liang Zhang, Chenrong Huang, andMi Liu*，A Multiple-Target Simultaneous Detection Method for Immunosorbent Assay and Immunospot Assay，Analytical Chemistry, 2022, 94, 8704−8714 (1区，IF=8.008).
(6) Lin Ma, Lu Diao, Zuofu Peng, Yun Jia, Huimin Xie, Baisong Li, Jianting Ma, Meng Zhang, Lifang Cheng, Dawei Ding, Xuenong Zhang, Huabing Chen, Fengfeng Mo, Honglv Jiang, Guoqiang Xu, Fenghua Meng, Zhiyuan Zhong,Mi Liu*, Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumour tissues or cells, Advanced Materials, 2021,43, 2104849 (1区，IF =32.086).
